Crossbow Therapeutics
Biotech · United States · private
Crossbow Therapeutics raised a $77M Series B co-led by Taiho Ventures and Arkin Bio Capital to finish the Phase 1 trial of CBX-250, an antibody that reaches cancer targets inside the cell.
The record
0 figures · 1 rounds · 13 backers · 1 feed items
Every one of them carries its source, its date, and its age when it has one. Reading the record takes a free account; the account is how you keep a watchlist.